The AI-Alibi Turnaround: Charles River marks its first organic growth since 2023 — and argues machine learning will fill its cages, not empty them

Book-to-bill hits a four-year high, margins inflect, and a +68% 90-day tape says the bottom is real.

CRL · Earnings Call · 2026-08-05

The bottom, marked in black ink

Birgit Girshick's first few months as CEO have an inflection point to show for it. In Q2 2026, Charles River posted its first total-company organic revenue growth since the third quarter of 2023 — a quiet 0.1%, but a line in the sand after eleven quarters of contraction. The DSA segment returned to organic growth (+0.2%) and, more importantly, the forward indicators went vertical: “we delivered on our second quarter financial targets, exceeding our prior outlook for the quarter and that we are raising our financial guidance for the year” — Birgit Girshick, Chief Executive Officer · 2026-08-05. Net bookings hit $701M, DSA backlog reached $1.97B, and the net book-to-bill hit 1.19x — the highest in nearly four years and the third consecutive quarter above 1.0x. The tape has certainly seen it. CRL's 90-day return is +68% (up-17w), a violent re-rating off a cycle that peaked at $458 in 2021 and was still down roughly a third from that high at the turn of the year. The inflection shows up even in the lagging fundamentals — the latest 10-Q (Q1 2026, period ending April 24) reports Total revenue of $996M, flat year-over-year, with operating income of $120M. The call's non-GAAP Q2 shows the actual acceleration: operating margin of 20.5%, up 420 basis points sequentially, and EPS of $3.02, up 47% sequentially, ahead of the "at least 30%" guide.

AI: the friend that fills the cages

The most contrarian thing Birgit said all quarter was about pre-IND work and machine learning. The Street's reflexive fear is that AI drug discovery plus NAMs empties the animal lab. CRL's argument is the opposite: AI makes molecule design cheaper and faster, so more candidates survive to the regulated safety-assessment stage — the stage CRL actually owns. The Lilly TuneLab collaboration (CRL provides wet-lab data to train Lilly's AI models) is the proof-of-concept, and Birgit was blunt about the early evidence: “companies that are more AI native or drug discovery companies that use AI platforms, they're generally running more programs than a typical biotech” — Birgit Girshick, Chief Executive Officer · 2026-08-05. On the NAMs side, she drew a firm line on what this is — and is not — becoming:

There will never be a NAMs business for Charles River. It will always be a Safety Assessment business where we're integrating NAMs into our Safety Assessment workflows.
Birgit Girshick, Chief Executive Officer · 2026-08-05

That is a meaningful strategic position: AI and post-IND work are the tail, but the regulated whole-animal study is the dog. As recently as the May call, the posture was noticeably more tentative — “It's very early days. There's so few programs in the pipeline that are AI assisted” — Birgit Girshick, Chief Executive Officer · 2026-05-07 — so the firming of that thesis into an active collaboration is genuinely new for this company, and it sits well with the global tape, where AI-infrastructure and reasoning-model keywords dominate the 360-day advancers.

The NHP moat and the margin machine

The other company-unique lever is nonhuman primate supply. Owning the Cambodian (K.F.) and Mauritius farms gives CRL something competitors increasingly lack: control of quality, timing, and cost. As demand for complex biologics (large molecules, GLP-1-adjacent programs) rises, the safety studies that require NHPs are exactly where CRL's win rate is improving. Pressed by David Windley on whether competitors were running short of NHP capacity, Birgit confirmed the edge: “We are in a very healthy state of having animals available.” — Birgit Girshick, Chief Executive Officer · 2026-08-05 The capture rate uptick is the early confirmation. The cost benefit lands mostly in Q4 (the K.F. ramp), which is the largest single piece of the "at least 500bp" second-half margin bridge — alongside the CDMO, Cell Solutions and European discovery divestitures that pushed Manufacturing's operating margin to 37.8%. This is also a balance-sheet story. CRL has deployed $300M of the $1B buyback at ~$174/share, ended Q2 at 2.5x net leverage, and raised free-cash-flow guidance to $400–420M. The trajectory keywords tell the same shift: last quarter's movers were "Pathway to Purpose" and "margin improvement"; the decliners — the “timing of NHP shipments” — Glenn Coleman, Executive Vice President and Chief Financial Officer · 2026-08-05 worry and "efficiency initiatives" — are precisely the themes being retired as the story pivots from cost-out to growth.

A different wave than the tape

The global keyword set this quarter is obsessed with the tariff-refund trade — IEEPA tariffs, tariff refund benefits and tariff expense are everywhere in the 90-day tape and across recent reporters. CRL is conspicuously absent from that trade. It is riding a different, quieter wave: biopharma demand recovery, with biotech funding near $100B trailing-twelve-months, IPO windows reopening, and global pharma finally past its restructuring. That is the thread connecting CRL's bookings surge to the new reporters — AbbVie, Amgen, Gilead and Lilly all printing with strong clinical and pipeline language. The risk is the tax code, not the tariff code: the Mauritius tax legislation change is a modeled $0.20 EPS headwind, offsetting the $0.19 one-time deferred-compensation benefit. With Investor Day set for September 24, the next leg of the story — the long-term margin algorithm and the AI-enabled portfolio — gets a proper airing. For a company that marked its bottom with a 0.1% print, that is the moment the recovery stops being an argument and starts being a plan.